Results 231 to 240 of about 665,029 (266)
Some of the next articles are maybe not open access.

Preclinical Safety Profile of Brimonidine

European Journal of Ophthalmology, 1996
Brimonidine is a selective α2-adrenergic agonist developed for lowering intraocular pressure in glaucoma patients. Since brimonidine will be used in long-term theraphy, the safety of this drug is an important feature for its clinical success. Brimonidine has been evaluated in a number of safety studies using doses much greater than
O V, Angelov   +5 more
openaire   +2 more sources

Propranolol Safety Profile in Children

Current Drug Safety, 2011
Data regarding the use of propranolol in pediatrics are limited despite its widespread use in adults. Since 1984, Propranolol has been used for the prevention of portal hypertensive hemorrhage in pediatric patients. Recently it has been also used for the management of hemangiomas in addition to other indications.
Mortada, El-Shabrawi, Fetouh, Hassanin
openaire   +2 more sources

Improving the safety profile of warfarin

Seminars in Hematology, 2002
Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic information in the future, along with current
S Jean, Chai, B Gail, Macik
openaire   +2 more sources

A Profile for Safety Critical Java

10th IEEE International Symposium on Object and Component-Oriented Real-Time Distributed Computing (ISORC'07), 2007
We propose a new, minimal specification for real-time Java for safety critical applications. The intention is to provide a profile that supports programming of applications that can be validated against safety critical standards such as DO-178B [15].
Bent Thomsen   +2 more
exaly   +3 more sources

Clinical safety profile of cefodizime

Journal of Antimicrobial Chemotherapy, 1990
Data from ten clinical trials involving 1189 patients treated with 1 g bd of cefodizime iv or im were analysed for adverse effects and abnormal laboratory test results. In total, side-effects possibly or probably related to cefodizime occurred in only 1.34% of patients.
openaire   +2 more sources

Methotrexate: Improving safety profile

Australasian Journal of Dermatology, 2006
SUMMARYOver the past 10 years, there have been 137 patient safety incidents in England associated with methotrexate prescribing. Recent reports show that Australia has similar concerns. Using the valuable tool of an audit, we reviewed our departmental prescribing practices for 49 patients with psoriasis on methotrexate.
Claire, Grills, Susan, Burge
openaire   +2 more sources

Safety Profile of the Fluoroquinolones

Drug Safety, 2010
The fluoroquinolone class of antibacterial agents are among the most frequently prescribed drugs, with utility in a broad range of bacterial infections. Although very useful agents, the fluoroquinolones as a class are associated with a number of adverse events, some with considerable clinical significance. In the past 15-20 years, tolerability concerns
openaire   +2 more sources

Safety Profile of Intravenous Bisphosphonates

Seminars in Oncology, 2007
Because of their proven efficacy, intravenous bisphosphonates play an important role in reducing the risk of skeletal-related events including pathologic fractures, spinal cord compression, and palliative radiotherapy to bone in patients with malignant bone lesions. Overall, intravenous bisphosphonates have an acceptable safety profile and are commonly
openaire   +2 more sources

The cardiovascular safety profile of escitalopram

European Neuropsychopharmacology, 2013
The cardiovascular effects of escitalopram were examined in a large group of participants in double-blind, randomized, placebo-controlled studies. Escitalopram (n=3298) was administered at doses between 5 and 20mg/day. Patients were treated in acute (8-12 weeks) and long-term (24 weeks) studies.
Michael E, Thase   +3 more
openaire   +2 more sources

Nonclinical Safety Profile of Tolvaptan

Cardiovascular Drugs and Therapy, 2011
In the present study, the nonclinical safety profile of tolvaptan was evaluated.A series of safety pharmacology and toxicology studies were performed in vitro and in mice, rats, dogs, rabbits and guinea pigs.In safety pharmacological studies, tolvaptan had no adverse effects on the central nervous, somatic nervous, autonomic nervous, smooth muscle ...
Akihide, Oi   +15 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy